Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood ...

MORF-057 is under clinical development by Eli Lilly and Co and currently in Phase II for Crohn's Disease (Regional Enteritis).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...